Evidence map›Paper›PMID 26151309›Full record

ArticleVirulence2015

Tackling tuberculosis: Insights from an international TB Summit in London.

Arundhati Maitra, Cynthia A Danquah, Francesca Scotti, Tracey K Howard, Tengku K Kamil, Sanjib Bhakta

Abstract readConference Proceedings
In one paragraph

Article in Virulence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arundhati Maitraa Mycobacteria Research Laboratory ; Institute of Structural and Molecular Biology; Birkbeck ; University of London , Malet Street, Bloomsbury, London WC1E 7HX , United Kingdom.
Cynthia A Danquaha Mycobacteria Research Laboratory ; Institute of Structural and Molecular Biology; Birkbeck ; University of London , Malet Street, Bloomsbury, London WC1E 7HX , United Kingdom.
Francesca Scottia Mycobacteria Research Laboratory ; Institute of Structural and Molecular Biology; Birkbeck ; University of London , Malet Street, Bloomsbury, London WC1E 7HX , United Kingdom.
Tracey K Howarda Mycobacteria Research Laboratory ; Institute of Structural and Molecular Biology; Birkbeck ; University of London , Malet Street, Bloomsbury, London WC1E 7HX , United Kingdom.
Tengku K Kamila Mycobacteria Research Laboratory ; Institute of Structural and Molecular Biology; Birkbeck ; University of London , Malet Street, Bloomsbury, London WC1E 7HX , United Kingdom.
Sanjib Bhaktaa Mycobacteria Research Laboratory ; Institute of Structural and Molecular Biology; Birkbeck ; University of London , Malet Street, Bloomsbury, London WC1E 7HX , United Kingdom.

Funding

Medical Research Council G0801956Wellcome Trust
6 · The paper itself

Abstract

Tuberculosis (TB) poses a grave predicament to the world as it is not merely a scientific challenge but a socio-economic burden as well. A prime cause of mortality in human due to an infectious disease; the malady and its cause, Mycobacterium tuberculosis have remained an enigma with many questions that remain unanswered. The ability of the pathogen to survive and switch between varied physiological states necessitates a protracted therapeutic regimen that exerts an excessive strain on low-resource countries. To complicate things further, there has been a significant rise of antimicrobial resistance. Existing control measures, including treatment regimens have remained fairly uniform globally for at least half a century and require reinvention. Overcoming the societal and scientific challenges requires an increase in dialog to identify key regions that need attention and effective partners with whom successful collaborations can be fostered. In this report, we explore the discussions held at the International TB Summit 2015 hosted by EuroSciCon, which served as an excellent platform for researchers to share their recent findings. Ground-breaking results require outreach to affect policy design, governance and control of the disease. Hence, we feel it is important that meetings such as these reach a wider, global audience.

Indexed as

Drug Resistance, BacterialAntitubercular AgentsCommunicable Disease ControlGlobal HealthHumansMycobacterium tuberculosisTuberculosisAntitubercular Agentsantibiotic resistancediagnosisdrug susceptibility testinglatencyMycobacteriumnew drug discoveryrepurposing drugstreatmenttuberculosisvaccine

Identifiers

PMID26151309
PMCPMC4720247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.